Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Survey on the Under-treatment of hypercholeSterolemia (EPHESUS Trial) (EPHESUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02608645
Recruitment Status : Unknown
Verified November 2015 by Murat Biteker, Muğla Sıtkı Koçman University.
Recruitment status was:  Not yet recruiting
First Posted : November 20, 2015
Last Update Posted : November 20, 2015
Sponsor:
Information provided by (Responsible Party):
Murat Biteker, Muğla Sıtkı Koçman University

Brief Summary:
In this study, within the secondary prevention group patients ( diabetes mellitus, coronary artery disease, peripheral artery disease, who have had events atherosclerotic cerebrovascular ) , statin use requirement , patients compliance and reaching target LDL-cholesterol levels (according to European guidelines ) will be evaluated.

Condition or disease
Hyperlipidemias

Detailed Description:

In the majority of patients treated with lipid lowering agents are not under control in accordance with the lipids manual. In this study, within the secondary prevention group patients ( diabetes mellitus, coronary artery disease, peripheral artery disease, who have had events atherosclerotic cerebrovascular ) , statin use requirement , patients compliance and reaching target LDL-cholesterol levels (according to European guidelines ) will be evaluated.

The investigators' aim is to determine the role of education and knowledge in reaching target LDL cholesterol levels in these patients. İn addition , the investigators want to emphasize in high-risk patients who are receiving or not receiving cholesterol-lowering treatment what is their target values , (LDL < 100 mg / dL and high -risk patients with LDL < 70 mg / dL in very high-risk patients ) and to determine what is the rate of patients and to the importance of reaching their target cholesterol levels. İn addition ,to evaluate the patients habits of the using statin dose .After screening , physician treatment decisions and reasons will be documented.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 6000 participants
Time Perspective: Prospective
Official Title: Evaluation of Perceptions, Knowledge and Compliance With tHE Guidelines for Secondary Prevention in Real Life Practice: A Survey on the Under-treatment of hypercholeSterolemia (EPHESUS Trial)
Study Start Date : November 2015
Estimated Primary Completion Date : September 2016
Estimated Study Completion Date : September 2016

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. The number of patients with secondary prevention group receiving appropriate lipid lowering therapy [ Time Frame: 2 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients receiving lipid-lowering therapy within the secondary prevention group in Turkey
Criteria

Inclusion Criteria:

  • Patients with coronary artery disease (acute coronary syndromes, post- myocardial infarction patients, who have a history of percutaneous coronary intervention , history of coronary artery by-pass graft )
  • Patients with carotid artery lesions or peripheral artery disease ,
  • Type 2 diabetes mellitus patients

Exclusion Criteria:

  • acute coronary syndrome in last 1 month
  • pregnancy or the first 6 months postpartum
  • ICU patients or emergency patients...etc.(other than polyclinic)